Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose naltrexone induction for mild to moderate Crohn's disease
NL-OMON52463Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing LDN induction with Placebo induction (2 arms). Started Jan 2021; status: completed.
02
Drugs
naltrexone
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON52463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52463.